Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 18, 2026, 2:06 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 697–720 of 3,526 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Non Insulin Dependent Diabetes Mellitus Clear all
Recruiting Not applicable Interventional

Black Impact: The Mechanisms Underlying Psychosocial Stress Reduction in a Cardiovascular Health Intervention

NCT06055036
View directory record Official record
Conditions
Cardiometabolic Syndrome, Physical Inactivity, Hypertension, Type 2 Diabetes, PreDiabetes, Obesity, Cardiovascular Diseases, Smoking, Sleep, Hyperlipidemias, Diet, Healthy, Blood Pressure
Interventions
Black Impact Intervention
Behavioral
Lead sponsor
Ohio State University
Other
Eligibility
18 Years and older · Male only
Enrollment
340 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
1
States / cities
Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Oct 6, 2025 · Synced Oct 18, 2026, 2:06 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Diabetes Smoking Cessation Incentives Study

NCT04682067
View directory record Official record
Conditions
Smoking Cessation, Diabetes Type 2
Interventions
Contingency Management, Usual Care smoking cessation
Behavioral
Lead sponsor
University of Oklahoma
Other
Eligibility
18 Years to 75 Years
Enrollment
29 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2022
U.S. locations
1
States / cities
Oklahoma City, Oklahoma
Source: ClinicalTrials.gov public record
Updated May 26, 2022 · Synced Oct 18, 2026, 2:06 PM EDT
Not yet recruiting Phase 3 Interventional

A Study of Orforglipron (LY3502970) Compared With Dulaglutide in Pediatric Participants With Type 2 Diabetes

NCT07668336
View directory record Official record
Conditions
Diabetes Mellitus, Type 2
Interventions
Orforglipron, Dulaglutide
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
10 Years to 17 Years
Enrollment
170 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2030
U.S. locations
17
States / cities
Sacramento, California • San Diego, California • Stamford, Connecticut + 14 more
Source: ClinicalTrials.gov public record
Updated Sep 25, 2026 · Synced Oct 18, 2026, 2:06 PM EDT
Completed Not applicable Interventional

Diabetes Coaching Program for Medicare Advantage Members With Type 2 Diabetes - Impact on A1c

NCT03363100
View directory record Official record
Conditions
Diabetes Mellitus, Type 2
Interventions
Digital health Partnership program
Behavioral
Lead sponsor
Evidation Health
Industry
Eligibility
18 Years and older
Enrollment
624 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
1
States / cities
San Mateo, California
Source: ClinicalTrials.gov public record
Updated Aug 1, 2019 · Synced Oct 18, 2026, 2:06 PM EDT
Completed Phase 2 Interventional Accepts healthy volunteers

Vitamin D, Glucose Control and Insulin Sensitivity in African-Americans

NCT00784511
View directory record Official record
Conditions
Type 2 Diabetes
Interventions
cholecalciferol, microcrystalline cellulose
Dietary Supplement · Other
Lead sponsor
Tufts University
Other
Eligibility
40 Years and older
Enrollment
100 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2011
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Nov 14, 2014 · Synced Oct 18, 2026, 2:06 PM EDT
Completed Not applicable Interventional

Cooking Matters for Diabetes - A 6-Week Program for Practical Application of Diabetes Self-Management Education

NCT04152811
View directory record Official record
Conditions
Diabetes Mellitus, Type 1 Diabetes, Type 2 Diabetes
Interventions
Cooking Matters for Diabetes, Usual Diabetes Care
Behavioral · Other
Lead sponsor
Ohio State University
Other
Eligibility
18 Years and older
Enrollment
48 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
1
States / cities
Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Jul 20, 2021 · Synced Oct 18, 2026, 2:06 PM EDT
Terminated Phase 3 Interventional

Effect of Inhaled Insulin (AERx® iDMS) on Blood Glucose Control in Type 2 Diabetes

NCT00411892
View directory record Official record
Conditions
Diabetes, Diabetes Mellitus, Type 2
Interventions
pioglitazone, inhaled human insulin
Drug
Lead sponsor
Novo Nordisk A/S
Industry
Eligibility
18 Years and older
Enrollment
196 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2008
U.S. locations
110
States / cities
Ozark, Alabama • Tuscaloosa, Alabama • Vestavia Hills, Alabama + 100 more
Source: ClinicalTrials.gov public record
Updated Sep 5, 2018 · Synced Oct 18, 2026, 2:06 PM EDT
Recruiting Not applicable Interventional Accepts healthy volunteers

Effect of Glucagon on Fasting Insulin Secretion and Glucose Metabolism in Subjects Without Type 2 Diabetes

NCT06424106
View directory record Official record
Conditions
PreDiabetes
Interventions
Glucagon, Glucose
Other
Lead sponsor
Mayo Clinic
Other
Eligibility
25 Years to 65 Years
Enrollment
60 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2027
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Apr 20, 2026 · Synced Oct 18, 2026, 2:06 PM EDT
Completed Phase 1 Interventional

Single Cohort, 2-Period Study to Assess Pharmacokinetics of Metformin Alone and in Combination With Ranolazine 500 mg

NCT01546558
View directory record Official record
Conditions
Type 2 Diabetes Mellitus
Interventions
Metformin, Ranolazine
Drug
Lead sponsor
Gilead Sciences
Industry
Eligibility
30 Years to 65 Years
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Jul 11, 2012 · Synced Oct 18, 2026, 2:06 PM EDT
Recruiting No phase listed Observational

HLA Demographics Study in Adults With Type 1 Diabetes

NCT06860516
View directory record Official record
Conditions
Diabetes Mellitus, Type I
Interventions
blood draw or cheek swab
Other
Lead sponsor
GentiBio, Inc
Industry
Eligibility
18 Years to 55 Years
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
5
States / cities
San Francisco, California • Gainesville, Florida • Boston, Massachusetts + 2 more
Source: ClinicalTrials.gov public record
Updated Aug 28, 2026 · Synced Oct 18, 2026, 2:06 PM EDT
Completed Phase 3 Interventional

Evaluation of the Effect on Glucose Control of AC2993 in Patients With Type 2 Diabetes Mellitus Treated With a Sulfonylurea

NCT00039026
View directory record Official record
Conditions
Diabetes Mellitus, Non-Insulin-Dependent
Interventions
AC2993, Placebo
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
16 Years to 75 Years
Enrollment
377 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2003
U.S. locations
126
States / cities
Anniston, Alabama • Birmingham, Alabama • Eclectic, Alabama + 99 more
Source: ClinicalTrials.gov public record
Updated Feb 24, 2015 · Synced Oct 18, 2026, 2:06 PM EDT
Completed Not applicable Interventional

Lifestyle Management of CKD in Obese Diabetic Patients

NCT02276742
View directory record Official record
Conditions
Obesity, Type 2 Diabetes, Chronic Kidney Disease (CKD)
Interventions
Social Cognitive Theory, Monitoring
Behavioral · Other
Lead sponsor
NYU Langone Health
Other
Eligibility
40 Years and older
Enrollment
269 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2019
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jul 14, 2020 · Synced Oct 18, 2026, 2:06 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study of the Safety, Pharmacokinetics, and Pharmacodynamics of CNTO 3649 in Healthy Adults and Patients With Type 2 Diabetes Mellitus

NCT00882726
View directory record Official record
Conditions
Diabetes Mellitus, Type 2
Interventions
CNTO 3649 IV (Healthy participants), CNTO 3649 SC (Healthy participants), CNTO 3649 SC (Diabetic patients), Placebo
Drug
Lead sponsor
Centocor, Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
133 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2010
U.S. locations
3
States / cities
Miramar, Florida • San Antonio, Texas • Tacoma, Washington
Source: ClinicalTrials.gov public record
Updated Dec 16, 2013 · Synced Oct 18, 2026, 2:06 PM EDT
Completed Phase 1 Interventional

TAK-875 Glimepiride Drug-Interaction Study

NCT01496443
View directory record Official record
Conditions
Pharmacokinetics
Interventions
TAK-875 and Glimepiride
Drug
Lead sponsor
Takeda
Industry
Eligibility
18 Years to 68 Years
Enrollment
28 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012
U.S. locations
1
States / cities
San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Sep 13, 2012 · Synced Oct 18, 2026, 2:06 PM EDT
Completed Phase 1Phase 2 Interventional Results available

Effect of LIK066 on Glucose Absorption in Patients With Type 2 Diabetes Mellitus

NCT01915849
View directory record Official record
Conditions
Type 2 Diabetes Mellitus
Interventions
LIK066, Placebo
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years to 65 Years
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
1
States / cities
Chula Vista, California
Source: ClinicalTrials.gov public record
Updated Feb 6, 2015 · Synced Oct 18, 2026, 2:06 PM EDT
Active, not recruiting Early Phase 1 Interventional

Subclinical Primary Aldosteronism in Diabetes At-Risk for Kidney Disease

NCT06190158
View directory record Official record
Conditions
Type 2 Diabetes, Chronic Kidney Diseases
Interventions
Oral sodium suppression test, Saline suppression test, Captopril suppression test, Dexamethasone suppression test, Cosyntropin stimulation test
Diagnostic Test
Lead sponsor
Brigham and Women's Hospital
Other
Eligibility
18 Years to 80 Years
Enrollment
125 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2029
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Aug 13, 2026 · Synced Oct 18, 2026, 2:06 PM EDT
Completed Phase 3 Interventional

An Open-Label Study Examining the Long-Term Safety of Exenatide Given Twice Daily to Patients With Type 2 Diabetes Mellitus

NCT01876849
View directory record Official record
Conditions
Type 2 Diabetes Mellitus
Interventions
exenatide
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
30 Years to 75 Years
Enrollment
275 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2008
U.S. locations
1
States / cities
Renton, Washington
Source: ClinicalTrials.gov public record
Updated Feb 24, 2015 · Synced Oct 18, 2026, 2:06 PM EDT
Not listed Not applicable Interventional

Treatment of Type 2 Diabetes With Ketogenic Diet

NCT03652649
View directory record Official record
Conditions
Type2 Diabetes Mellitus, Obesity
Interventions
3:1 ratio Ketogenic diet
Other
Lead sponsor
Mid-Atlantic Epilepsy and Sleep Center, LLC
Other
Eligibility
18 Years to 70 Years
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2020
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Aug 29, 2018 · Synced Oct 18, 2026, 2:06 PM EDT
Completed Phase 3 Interventional Results available

Efficacy and Safety of BI 1356 in Combination With Metformin in Patients With Type 2 Diabetes

NCT00622284
View directory record Official record
Conditions
Diabetes Mellitus, Type 2
Interventions
Placebo identical to BI 1356 5mg, Placebo identical to Glimepiride 1mg or 2mg or 3mg or 4 mg, BI 1356, Glimepiride
Drug
Lead sponsor
Boehringer Ingelheim
Industry
Eligibility
18 Years to 80 Years
Enrollment
1,560 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2008
U.S. locations
23
States / cities
Tempe, Arizona • Chula Vista, California • Los Angeles, California + 19 more
Source: ClinicalTrials.gov public record
Updated Jan 29, 2014 · Synced Oct 18, 2026, 2:06 PM EDT
Completed No phase listed Observational

SGLT2 Inhibition in Diabetes and Heart Failure

NCT02862067
View directory record Official record
Conditions
Diabetes Mellitus, Type 2, Heart Failure, Systolic
Interventions
Assessment of cardiorespiratory fitness
Other
Lead sponsor
Virginia Commonwealth University
Other
Eligibility
18 Years and older
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
1
States / cities
Richmond, Virginia
Source: ClinicalTrials.gov public record
Updated Jul 16, 2018 · Synced Oct 18, 2026, 2:06 PM EDT
Completed Not applicable Interventional

A Continuous Glucose Monitor Based Insulin Bolus Calculator

NCT05229445
View directory record Official record
Conditions
Diabetes Mellitus, Type 2, Diabetes Mellitus, Type 1
Interventions
continuous glucose monitor based insulin bolus calculator
Device
Lead sponsor
Welldoc
Industry
Eligibility
18 Years and older
Enrollment
27 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Oct 13, 2022 · Synced Oct 18, 2026, 2:06 PM EDT
Completed Phase 3 Interventional Results available

A Study Assessing Saxagliptin Treatment in Subjects With Type 2 Diabetes Who Are Not Controlled With Diet and Exercise

NCT00374907
View directory record Official record
Conditions
Type 2 Diabetes
Interventions
Saxagliptin, Placebo, Metformin (blinded), Metformin (open-label)
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 70 Years
Enrollment
156 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2009
U.S. locations
3
States / cities
San Diego, California • Baton Rouge, Louisiana • San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated May 7, 2015 · Synced Oct 18, 2026, 2:06 PM EDT
Completed Phase 1 Interventional

A Study to Evaluate Pharmacokinetics of LY3209590 in Pediatric Participants With Type 2 Diabetes Mellitus

NCT06362265
View directory record Official record
Conditions
Type 2 Diabetes Mellitus
Interventions
LY3209590
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
10 Years to 17 Years
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
10
States / cities
Los Angeles, California • Atlanta, Georgia • Columbus, Georgia + 7 more
Source: ClinicalTrials.gov public record
Updated Mar 24, 2026 · Synced Oct 18, 2026, 2:06 PM EDT
Completed No phase listed Observational

Non-traditional Cardiovascular Risk Factors and Atherosclerosis in Type 2 Diabetes

NCT00256607
View directory record Official record
Conditions
Type 2 Diabetes Mellitus
Interventions
Not listed
Lead sponsor
US Department of Veterans Affairs
Federal
Eligibility
40 Years and older
Enrollment
301 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
7
States / cities
Phoenix, Arizona • Tucson, Arizona • Long Beach, California + 4 more
Source: ClinicalTrials.gov public record
Updated Jun 27, 2014 · Synced Oct 18, 2026, 2:06 PM EDT